Compare Ascendis Pharma A/S (ASND) vs Lithium Americas Corp (LAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lithium Americas Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Lithium Americas Corp trades at $3.29 (market cap $1.16B). The key difference: Ascendis Pharma A/S is far larger — about 15.3× Lithium Americas Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| ASND | LAC | |
|---|---|---|
Market Cap | $17.74B | $1.16B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $10.05 |
52-Week Low | $163.32 | $2.55 |
Enterprise Value | $18.11B | $1.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lithium Americas (LAC) trades at $3.32, down 6.74% on the day, reflecting ongoing bearish pressure. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company remains unprofitable with negative net income of -$122.09 million in 2025, though it maintains a low P/B ratio of 0.87. Recent news highlights construction milestones at Thacker Pass and significant government funding interest in the rare earth sector.
LAC presents a high-risk, high-reward opportunity tied to its Thacker Pass project execution. Analyst consensus is cautiously optimistic with a $6.25 price target, but near-term risks include substantial capital needs, potential equity dilution, and persistent negative cash flow from operations. The stock's outlook hinges on successful project development and lithium market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
